Serum mycospecific immunoglobulins, particularly IgG and IgA, can vary during anti-TB treatment, reflecting antigenic load and immune response. In drug-sensitive TB, levels often decline progressively with effective therapy due to reduced mycobacterial burden, while in some cases IgA may persist longer, indicating ongoing mucosal immune activation. Monitoring these antibodies can provide adjunctive information on treatment response, but they are not standalone markers and should be interpreted alongside microbiological and clinical data.

Serodiagnostic for tuberculosis diagnostics is not taken into account after year 2010. I had done my ph d thesis from 1999 to2004. My this paper was published when immunodiagnostics was in use. I had reported serum biomarkers for tuberculosis, the tests are simple, cost-effective, at point of care study, sensitive, reproducible. I request to go through my concerned papers and to put valuable, critical comments on those.